Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target
Citizens analyst Silvan Turkcan reiterates Taysha Gene Therapies (NASDAQ: TSHA ) with a Market Outperform and maintains $11 price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.